Currax Pharmaceuticals

Focus: Currax Pharmaceuticals is a specialty pharmaceutical company focused on small molecules in neurology, with a portfolio anchored by established brands like TREXIMET and SILENOR. Based in Brentwood, TN, the company operates as a specialty pharma player with significant revenue concentration in marketed products.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Currax Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Currax Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

1 in 5yr

SILENOR

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

TREXIMET

Migraine attacks, cluster headache

$1M Part D

LOE Approaching

Help build intelligence for Currax Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established revenue base with three NDA-approved products generating measurable Part D spending ($1M+ for TREXIMET)
Neurology focus with expansion into obesity treatment (Naltrexone-Bupropion Phase 4, Contrave real-world evidence studies)
Late-stage pipeline with Phase 3 sumatriptan nasal powder and Phase 4 programs offering near-term value creation opportunities

Watch Out For

TREXIMET (45% of revenue) faces patent cliff in April 2026, creating material revenue headwind with no disclosed lifecycle replacement strategy
Limited hiring activity (zero active job openings at analysis date) and no visible R&D intensity metrics suggest constrained growth investment

Generated by Claude from Currax Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Core revenue driver at 45% concentration but loses exclusivity in 18 months, triggering urgent commercial and pipeline risk.

SILENOR

Sleep maintenance, oral mucositis, head and neck cancer pain

$907K Part D

Peak4.3yr

Secondary revenue anchor with 4+ years of exclusivity remaining; modest $907K Part D spend reflects niche positioning.

ONZETRA XSAIL

Migraine disorders, migraine without aura

$509K Part D

Peak8.4yr

Differentiated nasal powder formulation with longest LOE tail (10+ years); smallest revenue contributor but represents newer delivery innovation.

Pipeline & Clinical Trials

Drug Utilisation of Mysimba/Contrave

Obesity

N/A

Clinical Trials (1)

NCT06089824Drug Utilisation of Mysimba/Contrave

N/A

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

Obesity

N/A

Clinical Trials (1)

NCT06090461Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

N/A

Antipyrine and Benzocaine otic solution

Acute Otitis Media

Phase 2

Clinical Trials (1)

NCT02037893Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media

Phase 2

sumatriptan nasal powder

Acute Migraine With or Without Aura

Phase 3

Clinical Trials (1)

NCT03338920Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

Phase 3

Naltrexone-Bupropion

Obesity

Phase 4

Clinical Trials (1)

NCT06098079Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Phase 4

Triptan

Workplace Migraine Treatment

Phase 4

Silenor 6 mg

Healthy

Phase 4

Clinical Trials (1)

NCT02353299Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers

Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 approved products, 6 clinical trials

Top TAs: Neurology, Metabolic Diseases, Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Peak2 (67%)

Post-LOE1 (33%)

3 total products

Therapeutic Area Focus

Neurology

2 marketed1 pipeline

Metabolic Diseases

3 pipeline

Oncology

1 marketed

Marketed

Pipeline

Currax Pharmaceuticals

About Currax Pharmaceuticals

Why Work Here

Key Products

Watch Out For

Products & Portfolio (2)

Key Products by Revenue

Pipeline & Clinical Trials

Open Jobs (0)